logo-loader

Tiziana Life Sciences: A different approach, tackling disease using a safe, nasal and oral antibody

Published: 09:58 22 Sep 2021 BST

Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)'s investment case is presented by Proactive Research Analyst John Savin who takes viewers through their activities and timeline of progress to come. 


The firm deliver its fully human therapeutic antibody, foralumab, to the gut or nose mucosal surfaces aiming to modulate the immune response. Savin says this might help to control various autoimmune diseases such as Crohn’s and Multiple Sclerosis (MS).


Foralumab has also been clinically tested with interesting results in COVID-19 patients to alleviate any immune overreaction. Mucosal delivery is an innovative approach and foralumab is in early-stage clinical development.

 

Read Dr John Savin's outlook report: Controlling disease using a safe, nasal and oral antibody

Proactive Analyst expects "some good news over the next 1-2 months" from...

Proactive Research Analyst Robin Davison talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd (NASDAQ:TLSA), which focuses on what he expects from the clinical-stage biopharmaceutical company over the next few months. He says Tiziana is approaching a significant...

on 28/7/23